Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Market Closed 05-24 16:00:00 EDT

985.02

+4.45

+0.45%

盘后985.02

+0.000.00%

18:32 EDT

High995.41	Low983.16	Vol259.28K
Open984.04	D1 Closing980.57	Amplitude1.25%
Mkt Cap108.53B	Tradable Cap104.41B	Total Shares110.19M
T/O256.08M	T/O Rate0.24%	Tradable Shares106.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":985.02,"timestamp":1716580800000,"preClose":980.57,"halted":0,"volume":259277,"hourTrading":{"tag":"盘后","latestPrice":985.02,"preClose":985.02,"latestTime":"18:32 EDT","volume":12233,"amount":12049752.42,"timestamp":1716589961830},"delay":0,"floatShares":106000000,"shares":110185503,"eps":33.84642,"marketStatus":"Market Closed","change":4.45,"latestTime":"05-24 16:00:00 EDT","open":984.04,"high":995.405,"low":983.16,"amount":256079803.4576,"amplitude":0.012488,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":33.84642,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716883200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":980.57,"preHourTrading":{"tag":"盘前","latestPrice":981.2,"preClose":980.57,"latestTime":"09:00 EDT","volume":3,"amount":2966.16,"timestamp":1716555635338},"postHourTrading":{"tag":"盘后","latestPrice":985.02,"preClose":985.02,"latestTime":"18:32 EDT","volume":12233,"amount":12049752.42,"timestamp":1716589961830},"volumeRatio":0.7807564377145525,"overnightSupported":true,"impliedVol":0.1962,"impliedVolPercentile":0.0119},"requestUrl":"/m/hq/s/REGN/tweets","defaultTab":"tweets","newsList":[{"id":"2437926054","title":"Nvidia Stock Split Looks to Be First of Many in Tech, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2437926054","media":"Bloomberg","top":-1,"share":"https://ttm.financial/m/news/2437926054?lang=en_us&edition=fundamental","pubTime":"2024-05-25 07:30","pubTimestamp":1716593400,"startTime":"0","endTime":"0","summary":"Broadcom and Netflix among stocks with high price tagsStocks that split tend to perform well after, per BofA dataNvidia Corp. delighted investors when it announced a 10-for-1 stock split earlier this ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.bloomberg.com/news/articles/2024-05-24/nvidia-s-split-could-be-followed-by-others-in-tech-bofa-says","is_publish_highlight":true,"gpt_icon":1},{"id":"2438069632","title":"After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February","url":"https://stock-news.laohu8.com/highlight/detail?id=2438069632","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2438069632?lang=en_us&edition=fundamental","pubTime":"2024-05-25 02:00","pubTimestamp":1716573624,"startTime":"0","endTime":"0","summary":"The healthcare giant revealed that the breached data includes patient names, postal addresses, dates of birth, health diagnoses, and medication details.The nature of the cyberattack, which began on February 21, has not been disclosed.After filing a notice with government regulators, Cencora publicly acknowledged the breach on February 27.Despite the disclosure, the company has not revealed how many individuals were affected or how many have been notifiedto date.Mike Iorfino, a spokesperson for Cencora, confirmed these details in an email to TechCrunch.This incident is the latest in a series of cyberattacks targeting theU.S.healthcare sector. Recently,UnitedHealth Group Inc-owned Change Healthcare and Ascension’s hospital network experienced significant breaches andoperational disruptions.Related:USSenate Grills United Health’s Cyberattack Fallout, Ransom Payment.However, Cencora maintains “no connection” between its incident and those affecting Change Healthcare and Ascension.As a majo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KQ7DNgh45xCdSoXEGM3_eA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/664e8f221aa135d718f96f0c8b38c639","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KQ7DNgh45xCdSoXEGM3_eA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/664e8f221aa135d718f96f0c8b38c639"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unitedhealth-cyberattack-drug-distributor-cencora-180024077.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437748054","title":"Regeneron (REGN) Announces Positive Data on Oncology Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2437748054","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437748054?lang=en_us&edition=fundamental","pubTime":"2024-05-24 21:28","pubTimestamp":1716557280,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. REGN announced positive new results from an ongoing phase I/II study on pipeline candidate REGN7075.The phase I/II first-in-human, open-label study is evaluating REGN7075, in combination with oncology drug Libtayo . The study is currently enrolling patients with metastatic and locally advanced solid tumors who have exhausted standard treatment options.The trial includes an ongoing phase I dose-escalation portion and a phase II dose-expansion period. Patients first receive a weekly lead-in dose of REGN7075 monotherapy for three weeks to assess its safety and efficacy alone in the phase I dose-escalation portion. This is followed by treatment with combination therapy, wherein Libtayo is dosed once every three weeks and REGN7075 is dosed either every week or every three weeks.Efficacy results among these 51 patients showed a 6% (n=3) overall response rate  and 29%  disease control rate. This included one complete response , two partial responses  and 12 pat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-regn-announces-positive-data-132800850.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437748944","title":"BRIEF-Regeneron Says Promising Anti-Tumor Activity Of Novel Costimulatory Bispecific Antibody To Be Reported At Asco","url":"https://stock-news.laohu8.com/highlight/detail?id=2437748944","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437748944?lang=en_us&edition=fundamental","pubTime":"2024-05-24 06:54","pubTimestamp":1716504845,"startTime":"0","endTime":"0","summary":"May 23  - Regeneron Pharmaceuticals Inc :   * PROMISING ANTI-TUMOR ACTIVITY OF NOVEL COSTIMULATORY BISPECIFIC ANTIBODY REGN7075  IN COMBINATION WITH LIBTAYO  TO BE REPORTED AT ASCO   * REGENERON PHARMACEUTICALS- REGN7075 PHASE 1/2 TRIAL INVESTIGATING POTENTIALLY FIRST-IN-CLASS COMBINATION ACROSS RANGE OF ADVANCED SOLID TUMORSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437201127","title":"Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2437201127","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437201127?lang=en_us&edition=fundamental","pubTime":"2024-05-24 05:32","pubTimestamp":1716499923,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) said late Thursday that combination therapy of GN7075 and Libtayo, or cemiplimab, led to anti-tumor responses in patients with microsatellite stable colorectal cancer ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437171949","title":"Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2437171949","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2437171949?lang=en_us&edition=fundamental","pubTime":"2024-05-24 05:03","pubTimestamp":1716498180,"startTime":"0","endTime":"0","summary":"Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy. Ongoing REGN7075 Phase 1/2 trial is investigating a potentially first-in-class combination across a range of advanced solid tumors. “Microsatellite stable colorectal cancer has historically been unresponsive to immunotherapy,” said Neil H. Segal, M.D., Ph.D., Medical Oncologist and Research Director in the Division of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, and a trial investigator. “The early results for this novel investigational EGFRxCD28 costimulatory bispecific in combination with Libtayo are encouraging, showing anti-tumor responses in a highly difficult-to-treat cancer. This combination is one of the first immunotherapy regimens to show clinical activity in microsatellite stable colorectal cancer, and we are excited t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OBn5GKQBxPWKQ64h5BTqqw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OBn5GKQBxPWKQ64h5BTqqw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/promising-anti-tumor-activity-novel-210300569.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437320713","title":"Verona Pharma: Key Inflection Point Directly Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2437320713","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437320713?lang=en_us&edition=fundamental","pubTime":"2024-05-24 01:23","pubTimestamp":1716485012,"startTime":"0","endTime":"0","summary":"Verona Pharma plc stock has lost most of its gains from a strong rally late last year.However, the company has a pivotal FDA decision coming up next month around its primary candidate Ensifentrine.Ver","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1836752086/image_1836752086.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1836752086/image_1836752086.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4695314-verona-pharma-key-inflection-point-directly-ahead","is_publish_highlight":false,"gpt_icon":0},{"id":"2437176139","title":"Adicet Bio: Microcap With A High Risk To Reward Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2437176139","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437176139?lang=en_us&edition=fundamental","pubTime":"2024-05-23 23:06","pubTimestamp":1716476763,"startTime":"0","endTime":"0","summary":"Adicet Bio is a biotech company focused on developing off-the-shelf cell therapies for cancer and autoimmune diseases.They are currently conducting a phase 1 trial for their pilot cell therapy, ADI-00","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1348049615/image_1348049615.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1348049615/image_1348049615.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4695264-adicet-bio-microcap-with-a-high-risk-to-reward-ratio","is_publish_highlight":false,"gpt_icon":0},{"id":"2437296224","title":"Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?","url":"https://stock-news.laohu8.com/highlight/detail?id=2437296224","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2437296224?lang=en_us&edition=fundamental","pubTime":"2024-05-22 22:00","pubTimestamp":1716386426,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals' estimated fair value is US$1,903 based on 2 Stage Free Cash Flow to Equity. Regeneron Pharmaceuticals' US$994 share price signals that it might be 48% undervalued. Analyst price target for REGN is US$1,042 which is 45% below our fair value estimate. Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Regeneron Pharmaceuticals, Inc.  as an investment opportunity by taking the forecast future cash flows of the company and discounting them back to today's value. The Discounted Cash Flow  model is the tool we will apply to do this. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-nasdaq-regn-140026552.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437251231","title":"Wells Fargo Remains a Buy on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2437251231","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2437251231?lang=en_us&edition=fundamental","pubTime":"2024-05-22 17:16","pubTimestamp":1716369417,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-buy-on-regeneron-regn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-buy-on-regeneron-regn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2437110984","title":"Analysts Are Bullish on Top Healthcare Stocks: Progyny (PGNY), Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2437110984","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2437110984?lang=en_us&edition=fundamental","pubTime":"2024-05-21 20:11","pubTimestamp":1716293469,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Progyny (PGNY – Research Report) and Regeneron (REGN...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-progyny-pgny-regeneron-regn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-progyny-pgny-regeneron-regn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2437461779","title":"U.S. RESEARCH ROUNDUP- Chemed, PTC Therapeutics, Regeneron Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2437461779","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437461779?lang=en_us&edition=fundamental","pubTime":"2024-05-21 14:45","pubTimestamp":1716273903,"startTime":"0","endTime":"0","summary":"May 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Chemed, PTC Therapeutics and Regeneron Pharmaceuticals, on Tuesda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437489091","title":"Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM","url":"https://stock-news.laohu8.com/highlight/detail?id=2437489091","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2437489091?lang=en_us&edition=fundamental","pubTime":"2024-05-21 02:15","pubTimestamp":1716228900,"startTime":"0","endTime":"0","summary":"Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM. NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease  with evidence of type 2 inflammation. Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent  as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy  and evidence of type 2 inflammation . The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS study, with its data presented at a late-breaking session of the 2024 American Thoracic Society  International Conference and simultaneously published in the New England Journal of Medicine .34% reduction in moderate or severe ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OPTreMFV4QxkZ_hb1FVJzw--~B/aD0xNjc7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OPTreMFV4QxkZ_hb1FVJzw--~B/aD0xNjc7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/press-release-dupixent-breaking-data-181500176.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437510051","title":"Regeneron Eylea generics approved by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2437510051","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437510051?lang=en_us&edition=fundamental","pubTime":"2024-05-21 00:16","pubTimestamp":1716221810,"startTime":"0","endTime":"0","summary":"The U.S. FDA has approved two biosimilars for Regeneron Pharmaceuticals'  blockbuster eye drug Eylea .  Opufiz  from Samsung Biopesis and Yesafili  from Biocon were given the agency nod. However, when either product will actually launch is up in the air. A federal court judge in West Virginia on May 17 issued a temporary restraining order of 14 days blocking the launch of Eylea generics.  Given the expiration of key patents on Eylea, Regeneron developed and won approval of a high-dose version of Eylea in August 2023 that can be taken as infrequently as every 16 weeks after initial dosing. In 2023, Regeneron  reported ~$9.2B in Eylea  revenue.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468183222/image_1468183222.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468183222/image_1468183222.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108410-regeneron-eylea-generics-approved-by-fda","is_publish_highlight":false,"gpt_icon":0},{"id":"2436040101","title":"UPDATE 1-US FDA approves two biosimilars to blockbuster eye drug Eylea","url":"https://stock-news.laohu8.com/highlight/detail?id=2436040101","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436040101?lang=en_us&edition=fundamental","pubTime":"2024-05-20 23:00","pubTimestamp":1716217240,"startTime":"0","endTime":"0","summary":"(Adds details throughout)      May 20 (Reuters) - The U.S. Food and Drug Administration on Monday approved two close copies of Regeneron Pharmaceuticals'    blockbuster eye drug, Eylea, potentially hu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436055109","title":"US FDA approves Biocon unit's biosimilar to blockbuster eye drug Eylea","url":"https://stock-news.laohu8.com/highlight/detail?id=2436055109","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436055109?lang=en_us&edition=fundamental","pubTime":"2024-05-20 22:31","pubTimestamp":1716215489,"startTime":"0","endTime":"0","summary":"May 20  - The U.S. Food and Drug Administration on Monday approved Biocon    unit's biosimilar to Regeneron Pharmaceuticals'    blockbuster eye drug Eylea, according to information on the agency's website. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437548520","title":"Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2437548520","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2437548520?lang=en_us&edition=fundamental","pubTime":"2024-05-20 18:15","pubTimestamp":1716200100,"startTime":"0","endTime":"0","summary":"NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/20/2885069/0/en/Dupixent-dupilumab-Late-Breaking-Data-from-NOTUS-Confirmatory-Phase-3-COPD-Trial-Presented-at-ATS-and-Published-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2436428128","title":"U.S. RESEARCH ROUNDUP- Arista Networks, Crescent Energy, Dell Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2436428128","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436428128?lang=en_us&edition=fundamental","pubTime":"2024-05-20 14:56","pubTimestamp":1716188164,"startTime":"0","endTime":"0","summary":"May 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arista Networks, Crescent Energy and Dell Technologies on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":1},{"id":"2436918085","title":"Novo Nordisk, J&J lead R&D rankings in big pharma: report","url":"https://stock-news.laohu8.com/highlight/detail?id=2436918085","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436918085?lang=en_us&edition=fundamental","pubTime":"2024-05-19 02:52","pubTimestamp":1716058327,"startTime":"0","endTime":"0","summary":"Weight loss drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) have become the most transformative companies in big pharma, according to a new report bas","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1461608537/image_1461608537.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1461608537/image_1461608537.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma","is_publish_highlight":false,"gpt_icon":0},{"id":"2436189468","title":"Roche Is Joining The Obesity Party But Questions Remain","url":"https://stock-news.laohu8.com/highlight/detail?id=2436189468","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436189468?lang=en_us&edition=fundamental","pubTime":"2024-05-18 23:18","pubTimestamp":1716045533,"startTime":"0","endTime":"0","summary":"Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24.The full data presentation is needed to assess safety and tolerabili","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767278670/image_1767278670.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767278670/image_1767278670.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694321-roche-is-joining-the-obesity-party-but-questions-remain","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0866},{"period":"3month","weight":0.0039},{"period":"6month","weight":0.2339},{"period":"1year","weight":0.3586},{"period":"ytd","weight":0.1215}],"compareEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0475},{"period":"3month","weight":0.0425},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.2768},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.041845},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019407},{"month":5,"riseRate":0.647059,"avgChangeRate":0.064659},{"month":6,"riseRate":0.393939,"avgChangeRate":0.002817},{"month":7,"riseRate":0.636364,"avgChangeRate":0.053843},{"month":8,"riseRate":0.515152,"avgChangeRate":0.019343},{"month":9,"riseRate":0.484848,"avgChangeRate":0.029068},{"month":10,"riseRate":0.393939,"avgChangeRate":-0.00018},{"month":11,"riseRate":0.545455,"avgChangeRate":0.046018},{"month":12,"riseRate":0.515152,"avgChangeRate":0.048311}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction